Genmab As Stock Market Value
| GMAB Stock | USD 22.68 0.05 0.22% |
| Symbol | Genmab |
Genmab AS Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.634 | Earnings Share 1.71 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Genmab AS 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Genmab AS's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Genmab AS.
| 02/01/2025 |
| 03/03/2025 |
If you would invest 0.00 in Genmab AS on February 1, 2025 and sell it all today you would earn a total of 0.00 from holding Genmab AS or generate 0.0% return on investment in Genmab AS over 30 days. Genmab AS is related to or competes with Ascendis Pharma, Apellis Pharmaceuticals, Akero Therapeutics, Blueprint Medicines, Day One, Amylyx Pharmaceuticals, and Terns Pharmaceuticals. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark More
Genmab AS Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Genmab AS's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Genmab AS upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.28 | |||
| Information Ratio | 0.0873 | |||
| Maximum Drawdown | 10.76 | |||
| Value At Risk | (3.81) | |||
| Potential Upside | 4.24 |
Genmab AS Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Genmab AS's standard deviation. In reality, there are many statistical measures that can use Genmab AS historical prices to predict the future Genmab AS's volatility.| Risk Adjusted Performance | 0.0666 | |||
| Jensen Alpha | 0.1696 | |||
| Total Risk Alpha | 0.2383 | |||
| Sortino Ratio | 0.0844 | |||
| Treynor Ratio | 58.45 |
Genmab AS Backtested Returns
At this point, Genmab AS is very steady. Genmab AS holds Efficiency (Sharpe) Ratio of 0.0436, which attests that the entity had a 0.0436 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Genmab AS, which you can use to evaluate the volatility of the firm. Please check out Genmab AS's Market Risk Adjusted Performance of 58.46, risk adjusted performance of 0.0666, and Downside Deviation of 2.28 to validate if the risk estimate we provide is consistent with the expected return of 0.0991%. Genmab AS has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0029, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab AS's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab AS is expected to be smaller as well. Genmab AS right now retains a risk of 2.27%. Please check out Genmab AS maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to decide if Genmab AS will be following its current trending patterns.
Auto-correlation | 0.24 |
Weak predictability
Genmab AS has weak predictability. Overlapping area represents the amount of predictability between Genmab AS time series from 1st of February 2025 to 16th of February 2025 and 16th of February 2025 to 3rd of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Genmab AS price movement. The serial correlation of 0.24 indicates that over 24.0% of current Genmab AS price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.24 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Genmab AS lagged returns against current returns
Autocorrelation, which is Genmab AS stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Genmab AS's stock expected returns. We can calculate the autocorrelation of Genmab AS returns to help us make a trade decision. For example, suppose you find that Genmab AS has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Genmab AS regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Genmab AS stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Genmab AS stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Genmab AS stock over time.
Current vs Lagged Prices |
| Timeline |
Genmab AS Lagged Returns
When evaluating Genmab AS's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Genmab AS stock have on its future price. Genmab AS autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Genmab AS autocorrelation shows the relationship between Genmab AS stock current value and its past values and can show if there is a momentum factor associated with investing in Genmab AS.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Correlation, Genmab AS Volatility and Genmab AS Alpha and Beta module to complement your research on Genmab AS. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.